The Subdermal Contraceptive Implants Market was valued at USD 1.1 billion in 2024 and is projected to reach USD 1.14 billion in 2025 and USD 1.6 billion by 2034, growing at a CAGR of 3.90% during the forecast period 2025–2034, according to Polaris Market Research. Subdermal contraceptive implants are small rods inserted into the upper arm that steadily release hormones to prevent pregnancy for one to five years. Expansion is supported by growing awareness of long-acting reversible contraception methods, rising demand for reliable long-term options, and investment in the healthcare sector. North America was the largest regional market in 2024.

Long-Acting Reversible Contraception Gains Preference

Implants offer convenience, high effectiveness, and long-term birth control, placing long-acting reversible contraception at the center of market expansion. Polaris notes that women prefer these implants because they are safe, remain effective for three years without intervention, and can be easily removed. The devices work by modifying the endometrium, suppressing ovulation, and increasing the viscosity of cervical mucus.

Technological advancements and research and development efforts, together with new product launches and acquisitions by key players, further support the Subdermal Contraceptive Implants Market. Increasing demand for reliable and long-term contraceptive methods, coupled with healthcare sector investment, is driving the need for these devices.

Unintended Pregnancies Underscore the Need for Reliable Options

A significant driver is the rising number of unintended pregnancies worldwide. According to the United Nations Population Fund, unintended pregnancies account for approximately half of all pregnancies globally, with 121 million occurring yearly. Initiatives promoting contraceptive methods have gained traction in response.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/subdermal-contraceptive-implants-market

Polaris also cites rising abortions, technical advances, a growing population, and rising healthcare expenditure as demand factors, with increasing demand from China, Japan, and India. Global players are expanding their presence in developing countries to tap this potential. Increasing awareness of contraceptives, government initiatives for population control, changing lifestyles, disposable income, and the introduction of reasonable contraceptives by market performers also influence the market.

Levonorgestrel and Etonogestrel Implants Define the Product Landscape

By product, the market is segmented into the levonorgestrel implant and etonogestrel implant categories. The levonorgestrel implant segment held the largest market share in 2024. These flexible rods release a steady, low hormone dose, are highly effective with a very low failure rate due to continuous hormone release, and, depending on the product, can provide protection for 3 to 5 years. Once inserted, users need to take no further action, unlike daily pills, and fertility generally returns shortly after removal.

The etonogestrel implant category recorded high market demand in 2022, supported by population growth, population control initiatives, sexual health concerns, and increased healthcare expenditure in developing countries.

Affordability and Government Initiatives Broaden Access

Governments worldwide are taking initiatives to improve access, and insurance plans often cover FDA-approved birth control products. Tanzania and the United States are implementing measures to increase availability. The United Nations, in collaboration with manufacturers such as Bayer HealthCare's Jadelle, has worked to reduce prices in underdeveloped African economies.

Affordable contraceptive implants, such as the Sino-implant (II), are anticipated to gain popularity in Africa and Asia. Cost and affordability, however, are listed among the market's restraints. Government and supply measures contribute to the growing demand and scope of the market.

Competitive Landscape and Key Players

The Subdermal Contraceptive Implants  is characterized by intense competition, with established players relying on advanced technology, high-quality products, and strong brand image. Key players include Allergan plc, Bayer AG, Karex Industries, Mayer Laboratories, Merck & Co., Inc., Nexplanon, Reckitt Benckiser Group plc, Shanghai Dahua Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and The Female Health Company.

These companies use research and development, mergers and acquisitions, and technological innovation to expand product portfolios and maintain a competitive edge. Polaris rates rivalry among existing firms as high and the threat of new entrants as low. The market is segmented by product, implant, end-use, and region.

More Trending Latest Reports By Polaris Market Research:

gpu-server-market

earth-observation-small-satellite-market

trim-tabs-market

artificial-flowers-market

building-information-modeling-market

smart-pills-market

soybean-market

silica-flour-market

bioregenerative-aesthetic-injectables-market

industrial-dryer-market